Seikagaku Corporation

8 articles about Seikagaku Corporation

• Seikagaku Offers Free Back Health Education and Pre-Screenings at the Convoy of Hope Orlando Community Event

  7/27/2019

  Seikagaku Corporation, a Japanese pharmaceutical and medical device company focused on providing innovative drug discovery specializing in glycoscience, will be featured at the Convoy of Hope Orlando Community Event on July 27, 2019.

• Bioventus to Continue Distributing SUPARTZ FX Through 2028

  2/12/2018

  Under terms of this new agreement, Bioventus will be the exclusive distributor of SUPARTZ FX in the US through May 2028.

• Can-Fite BioPharma: Seikagaku Corporation, the Exclusive Licensee of CF101 in Japan, Is to Commence Phase I Clinical Trial in Japan With CF101 for the Treatment of Rheumatoid Arthritis

  8/18/2008

• Can-Fite BioPharma Progresses Through Clinical Trials: Completed Enrollment Of Half The Patients Required For Phase IIb RA Trial And Is Scheduled To Receive Next Payment Fom The Japanese Seikagaku Corporation

  10/23/2006

• Seikagaku Corporation Obtains Sales Distribution Approval For MukoUp

  10/20/2006

• Can-Fite BioPharma Out Licenses Rights For Its Drug, CF101, In Japan To The Seikagaku Corporation And Expects To Receive US$ 19.5 Million From Licensing Fees And Milestone Payments And Collect Substantial Royalties

  9/25/2006

• Seikagaku Corporation To Begin Clinical Trials Of Injectable Hyaluronic Acid Gel For Knee Osteoarthritis Treatment In US

  7/21/2006

• Discovery Partners International Inc. Announces Receipt Of Success Milestone Payment In Its Lead Finding Collaboration With Seikagaku Corporation

  11/9/2005